oral glp 1 inhibitors Orforglipron, an Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Peptidyl and Non-Peptidyl Oral Glucagon-Like
Description
doi: 10.3945/an.115.010322 18
Impact of Dysbiosis: An imbalance in gut bacteria (dysbiosis) can impair GLP-1 secretion, contributing to the drugs' lower effectiveness
Improvements in insulin resistance, measured using standard clinical indices, have been observed in some trials, though results vary between studies and appear to be more pronounced when weight loss is achieved
Recently, a federal panel ruled that the claims regarding vision loss should be independent from the gastrointestinal injury claims
